PLACMALVAC

Clinical development of a VAR2CSA-based placental malaria vaccine

 Coordinatore KOBENHAVNS UNIVERSITET 

 Organization address postcode: 1017

contact info
Titolo: Mr.
Nome: Ivan
Cognome: Kristoffersen
Email: send email
Telefono: +45 35322626
Fax: +45 35324612

 Nazionalità Coordinatore Denmark [DK]
 Totale costo 7˙863˙094 €
 EC contributo 5˙934˙980 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-03-01   -   2016-02-29

 Partecipanti

# participant  country  role  EC contrib. [€] 
1 KOBENHAVNS UNIVERSITET DK coordinator 2˙096˙620.00
2    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Dr.
Nome: Stefanie
Cognome: Bolte
Email: send email
Telefono: 4970710000000
Fax: 4970714684

DE (TUEBINGEN) participant 1˙013˙400.00
3    EXPRES2ION BIOTECHNOLOGIES APS

 Organization address address: AGERN ALLE 1
city: HORSHOLM
postcode: 2970

contact info
Titolo: Dr.
Nome: Willem Adriaan
Cognome: De Jongh
Email: send email
Telefono: +45 26394649

DK (HORSHOLM) participant 996˙648.00
4    UNIVERSITE D ABOMEY CALAVI UAC

 Organization address address: CAMPUS UNIVERSITAIRES D ABOMEY
city: ABOMEY CALAVI
postcode: 1

contact info
Titolo: Mr.
Nome: Cynel
Cognome: Kahoun
Email: send email
Telefono: +229 95199219

BJ (ABOMEY CALAVI) participant 904˙056.00
5    INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT

 Organization address address: Boulevard de Dunkerque - CS 90009 44
city: MARSEILLE
postcode: 13572

contact info
Titolo: Mr.
Nome: Jean
Cognome: Albergel
Email: send email
Telefono: +33 0 4 91 99 94 50
Fax: +33 0 4 91 99 92 12

FR (MARSEILLE) participant 488˙960.00
6    EUROPEAN VACCINE INITIATIVE - EEIG

 Organization address address: IM NEUERHEIMER FELD 307
city: Heidelberg
postcode: 69120

contact info
Titolo: Mr.
Nome: Sten
Cognome: Larsen
Email: send email
Telefono: +45 3042 3159

DE (Heidelberg) participant 435˙296.60

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

pregnant    protein    clinical    vaccine    women    optimize    expres    prepare    malaria    placental    first    biotechnologies    ion    antigens   

 Obiettivo del progetto (Objective)

'Placental malaria, a special form of malaria targeting pregnant women, causes the death of 200,000 infants and 10,000 pregnant women each year. Placental malaria has no sustainable cure. The overall success criterion of the proposed project is to enable the manufacture of a vaccine, which protects fetus and mother against the adverse effects of malaria during pregnancy. Administered to women before they get pregnant the vaccine should induce antibodies that prevent the binding of malaria parasites in the placenta. Vaccine development is facilitated by the availability of an in vitro assay that predicts clinical immunity. With this proposal, we seek funding to produce the first placental malaria vaccine and perform the first clinical studies in humans. In parallel, we will prepare a field site and a protocol for a phase II study in African women. The partners behind the application have secured funding for ongoing work to down-select the current VAR2CSA lead antigens and to produce GLP batch protein for toxicology studies in animals, prior to the initiation of the work proposed here. Under the proposed FP7 project an SME, ExpreS2ion Biotechnologies will optimize production and purification of the vaccine. ExpreS2ion Biotechnologies operates a unique expression platform and this project will enable the company to expand their business into downstream process development. The academic partners are strong. Researchers at University of Copenhagen, (UCPH) originally discovered the vaccine protein and they have been collaborating with Institut de Recherche pour le Developpement (IRD) and Université d'Abomey-Calavi (UAC) to optimize vaccine antigens and to prepare sites for clinical testing. The European Vaccine Initiative (EVI) will provide product management and coordinate execution of the phase I clinical trial. Thus, this study will provide a product to continue into efficacy studies in Africa, which could be initiated shortly after the end of the project.'

Altri progetti dello stesso programma (FP7-HEALTH)

GAMEXP (2009)

"Genomic approaches to metabolite exploitation from Xenorhabdus, Photorhabdus"

Read More  

EUROWESTNILE (2011)

European West Nile collaborative research project

Read More  

SYSTEMCERV (2012)

Systems biology approaches to cervical pre-cancer and cancer

Read More